Topical Medication Segment to Hold Larger Acne Medication Market Share During 2022-2030

According to our new research study on "Acne Medication Market Size and Forecast (2020-2030), Global and Regional Share, Trend, and Growth Opportunity Analysis," the market value is projected to grow from US$ 7,774.56 million in 2022 to US$ 11,802.29 million by 2030. The Acne Medication Market is further anticipated to record a CAGR of 5.40% from 2022 to 2030. The acne medication market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies. Key factors driving the market growth are the increasing prevalence of severe acne problems and the launch of novel drugs. However, side effects associated with acne medication limit the acne medication market growth. Moreover, acne medication market trends include the upsurge in need for organic and natural treatments.

The retinoid segment held the largest acne medication market share, based on therapeutic class, in 2022 and the same segment is anticipated to register a significant CAGR in the market during 2022-2030. Retinoids, which can be bought only with a doctor's prescription, contain vitamin A as a primary ingredient; they function similarly to retinol but are far more potent and more successful in treating acne. Retinoids are available as oral capsules and topical therapies. Tretinoin, adapalene, and isotretinoin are well-known retinoids; the oral formulation of isotretinoin is sometimes referred to as Roaccutane. Retinoids are frequently prescribed in dosages of 0.1-1% for topical applications and 0.5-1 mg for oral applications per kilogram of patient weight.

Based on formulation, the acne medication market is classified into topical medication and oral medication. The topical medication segment held the largest share of the acne medication market in 2022. The same segment is further anticipated to record a significant CAGR in the market from 2022 to 2030. Topical formulations play a vital role in managing and treating acne, offering targeted delivery of active ingredients directly to the affected skin areas. Various types of topical acne medication include gel, cream, lotion, foam, and solution, each tailored to address specific acne concerns and skin types. These formulations commonly contain ingredients such as retinoids, benzoyl peroxide, salicylic acid, and antibiotics, each serving distinct roles in combating acne breakouts.

Based on type, the global acne medication market is classified into prescription medicines and over-the-counter medicines. The prescription medicines segment held a largest acne medication market share in 2022. Dermatologists or healthcare providers typically prescribe medications after thoroughly assessing the individual's acne type, severity, and responsiveness to previous treatments. Prescription acne medications encompass a range of options, including topical treatments, oral medications, combination therapies, and specialized formulations tailored to address specific acne concerns. Prescription medications are meant to offer targeted and potent solutions for individuals with moderate to severe forms of the condition.

The acne medication market is segmented into retail stores, pharmacies, and drug stores based on mode. 2022 the pharmacies and drug stores segment held a larger market share. With their accessibility, privacy, and affordability (compared to private physicians), pharmacies and drug stores are vital health services, supplies, and knowledge sources. Pharmacies and drug stores have gained recognition in numerous nations in recent years for their ability to enhance health by aiding in the management of a broad range of illnesses and medical conditions. Pharmacies and drug stores often have knowledgeable staff to guide customers on selecting the right acne medication based on individual skin types and concerns.

Teva Pharmaceutical Industries Ltd, Mayne Pharma Group Ltd, Almirall SA, Johnson & Johnson, Sun Pharmaceutical Industries Ltd, Bausch Health Companies Inc, Centro Internacional de Cosmiatria SA de CV, Galderma SA, Pfizer Inc., GSK Plc, Viatris Inc, Somar Sapi De CV, Carnot Technologies, and Italmex SA are a few key companies profiled in the acne medication market report.

Companies operating in the acne medication market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the acne medication market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall acne medication market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

In September 2023, Cosmo Pharmaceuticals NV (Ireland) and Glenmark Specialty SA, a subsidiary of Glenmark Pharmaceuticals (Mumbai), announced signing distribution and licensing arrangements for the distribution of Winlevi (1% clascoterone cream) in South Africa and Europe. The agreements state that Glenmark will get sole rights to market Winlevi in 15 EU nations (Sapin, Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, and Sweden), as well as in South Africa and the UK, via Cassiopea, a Cosmo subsidiary.

In October 2023, Crown Therapeutics, a branch of Crown Laboratories, added two new PanOxyl products-PanOxyl Clarifying Exfoliant with 2% salicylic acid and PanOxyl Adapalene 0.1% gel-to its dermatologist-endorsed and award-winning PanOxyl range. In September 2023, Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, announced the accessibility of WINLEVI (clascoterone cream 1% w/w) in Canada. For patients 12 years of age and older, WINLEVI is the first and only androgen receptor inhibitor recommended for the topical treatment of acne vulgaris, or acne.


Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com